Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QPCT | Q16769 | 3/20 | 0.45 |
| ▸ | BMP1 | P13497 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | APLNR | P35414 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20871412 | 0.91 | HTT (0.42) | SLC6A4TAAR1HTTSMN1; SMN2APLNR | |
| SCHEMBL29336136 | 0.90 | QPCT (0.46) | QPCTBMP1GAACYP1A1CYP1A2 | |
| SCHEMBL22340948 | 0.85 | CNR1 (0.45) | SLC6A4MEN1KMT2ATAAR1HTT | |
| SCHEMBL20871164 | 0.85 | CNR1 (0.45) | SLC6A4MEN1KMT2ATAAR1HTT | |
| SCHEMBL29335346 | 0.85 | BMP1 (0.50) | QPCTBMP1GAACYP1A1CYP1A2 | |
| SCHEMBL22340950 | 0.84 | KMT2A (0.45) | MEN1KMT2ATAAR1HTTSMN1; SMN2 | |
| SCHEMBL29336228 | 0.84 | KMT2A (0.41) | GAASLC6A4MEN1KMT2ATAAR1 | |
| SCHEMBL22340951 | 0.84 | BCL2A1 (0.47) | MEN1KMT2ATAAR1HTTSMN1; SMN2 | |
| SCHEMBL22340961 | 0.84 | APP (0.44) | SLC6A4TAAR1HTTSMN1; SMN2APLNR | |
| SCHEMBL22340952 | 0.82 | CYP19A1 (0.44) | MEN1KMT2ATAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3707132-B1 | NEW METHOD FOR THE SYNTHESIS OF UNSYMMETRICAL TERTIARY AMINES | UNIV PARIS SACLAY (FR) | 2024-07-17 | — | — | EP | disclosed |
| US-11034646-B2 | Method for the synthesis of unsymmetrical tertiary amines | Universite Paris-Saclay (FR) | 2021-06-15 | — | — | US | disclosed |
| US-20200255369-A1 | NEW METHOD FOR THE SYNTHESIS OF UNSYMMETRICAL TERTIARY AMINES | Universite Paris-Saclay (FR) | 2020-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200255369-A1 | NEW METHOD FOR THE SYNTHESIS OF UNSYMMETRICAL TERTIARY AMINES | ADH1C, ADH1A, ADH5 | QPCT 988/4885BMP1 3634/4885GAA 4254/4885 |
| US-11034646-B2 | Method for the synthesis of unsymmetrical tertiary amines | ADH1C, PNMT, ADH1A | QPCT 998/4885BMP1 3800/4885GAA 4059/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.